Natera Inc (NASDAQ:NTRA) has been given a consensus recommendation of “Buy” by the eight brokerages that are covering the stock, MarketBeat reports. Three analysts have rated the stock with a hold recommendation, four have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $42.40.

Several research analysts have recently weighed in on the stock. Craig Hallum upped their price target on shares of Natera from $37.00 to $49.00 and gave the stock a “buy” rating in a report on Thursday, November 7th. BidaskClub raised shares of Natera from a “buy” rating to a “strong-buy” rating in a report on Tuesday, October 8th. Canaccord Genuity reaffirmed a “buy” rating and issued a $44.00 price target on shares of Natera in a report on Wednesday, October 16th. ValuEngine raised shares of Natera from a “hold” rating to a “buy” rating in a report on Friday, November 1st. Finally, Zacks Investment Research cut Natera from a “buy” rating to a “hold” rating in a research note on Tuesday.

In related news, CFO Michael Burkes Brophy sold 15,701 shares of the stock in a transaction on Monday, October 21st. The stock was sold at an average price of $40.00, for a total value of $628,040.00. Following the transaction, the chief financial officer now owns 16,005 shares of the company’s stock, valued at $640,200. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, COO Robert Alan Schueren sold 12,545 shares of the stock in a transaction on Friday, September 20th. The shares were sold at an average price of $33.19, for a total value of $416,368.55. Following the completion of the transaction, the chief operating officer now directly owns 25,000 shares in the company, valued at approximately $829,750. The disclosure for this sale can be found here. In the last three months, insiders sold 64,557 shares of company stock worth $2,241,958. 9.29% of the stock is owned by insiders.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in NTRA. Marshall Wace LLP bought a new position in Natera in the first quarter valued at $264,000. Focused Wealth Management Inc bought a new position in shares of Natera during the second quarter valued at about $83,000. Moody Aldrich Partners LLC grew its stake in shares of Natera by 16.9% during the second quarter. Moody Aldrich Partners LLC now owns 50,491 shares of the medical research company’s stock valued at $1,393,000 after buying an additional 7,286 shares during the last quarter. Los Angeles Capital Management & Equity Research Inc. bought a new position in shares of Natera during the second quarter valued at about $278,000. Finally, AGF Investments Inc. grew its stake in shares of Natera by 240.0% during the second quarter. AGF Investments Inc. now owns 170,000 shares of the medical research company’s stock valued at $4,689,000 after buying an additional 120,000 shares during the last quarter. 95.53% of the stock is currently owned by institutional investors and hedge funds.

Shares of Natera stock traded down $1.21 during trading on Monday, hitting $38.31. The stock had a trading volume of 336,500 shares, compared to its average volume of 681,420. The firm has a market cap of $2.62 billion, a price-to-earnings ratio of -17.82 and a beta of 1.45. Natera has a 12 month low of $11.08 and a 12 month high of $40.92. The business’s 50-day moving average is $36.76 and its 200 day moving average is $29.14. The company has a current ratio of 2.54, a quick ratio of 2.42 and a debt-to-equity ratio of 1.10.

Natera (NASDAQ:NTRA) last released its quarterly earnings results on Wednesday, November 6th. The medical research company reported ($0.33) earnings per share for the quarter, topping the consensus estimate of ($0.53) by $0.20. The firm had revenue of $77.90 million for the quarter, compared to analysts’ expectations of $73.97 million. Natera had a negative net margin of 42.45% and a negative return on equity of 312.89%. The business’s quarterly revenue was up 19.3% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.49) earnings per share. As a group, equities analysts expect that Natera will post -2.15 EPS for the current year.

Natera Company Profile

Natera, Inc, a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.

Further Reading: Diversification Important in Investing

Analyst Recommendations for Natera (NASDAQ:NTRA)

Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.